OpenRegistry
Companies House/Foresterhill/Company profile

ELASMOGEN LIMITED

Active
SC467513·incorporated 2014-01-15

ELASMOGEN LIMITED is an active UK private limited company, incorporated on 15 January 2014 at Companies House (number SC467513; OpenRegistry canonical ID GB-SC467513-elasmogen-limited). Sophymarine's OpenRegistry classifies it under SIC 72110 (Research and experimental development on biotechnology), one of 4,219 active UK entities in that code and one of 1 active companies registered in Foresterhill, Aberdeen (postcode AB25). Programmatic access via MCP at https://openregistry.sophymarine.com/mcp.

Status
Active
Type
Private Limited Company
Incorporated
2014-01-15
Registered Address
LIBERTY BUILDING, FORESTERHILL, ABERDEEN, AB25 2ZP
SIC
72110 — Research and experimental development on biotechnology
Country of origin
United Kingdom

Accounts

Last filed accounts made up to 2025-01-31. Next accounts due 2026-10-31. Financial year-end: 31/01. Filing class: FULL.

Confirmation statement

Last confirmation statement made up to 2026-01-15. Next confirmation statement due 2027-01-29.

Persons with significant control

ELASMOGEN LIMITED has 1 person with significant control on file:

  • The company has not yet completed all steps to find a PSC.
  • No individual or entity with significant control has been identified.

4 historical PSC records have ceased:

  • Kcp Nominees Ltd (England And Wales reg. 10830297). Notified 2021-01-29. Ceased 2022-04-29.
    • Owns 25–50% of shares
    • Holds 25–50% of voting rights
  • Dr Caroline Jane Barelle born 1970 resident in Uk, British national. Notified 2016-04-06. Ceased 2018-01-02.
    • Owns 25–50% of shares
    • Holds 25–50% of voting rights
  • (unnamed). Notified 2017-01-15. Ceased 2017-09-08.
  • (unnamed). Notified 2018-01-02. Ceased 2021-01-29.

Previous names

ELASMOGEN LIMITED has previously traded as:

  • PACIFIC SHELF 1760 LIMITED (until 2014-02-05)

Similar UK companies

Other companies registered under SIC 72110 (Research and experimental development on biotechnology):